Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RP 2

Next Previous
Drug Profile

RP 2

Alternative Names: RP-2

Latest Information Update: 13 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Replimune
  • Developer Bristol-Myers Squibb; Replimune; Roche
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Uveal melanoma
  • Phase II Colorectal cancer; Liver cancer
  • No development reported Solid tumours

Most Recent Events

  • 08 Jan 2025 Phase-II/III clinical trials in Uveal melanoma (Combination therapy, Metastatic disease, In children, In adolescents, In adults, In the elderly) in USA (Parenteral) (NCT06581406)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (Intratumoural)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom (Intratumoural)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top